, Singapore

Guardant Health AMEA wins the Oncology Product Innovation of the Year at Healthcare Asia Medtech Awards 2021

It was recognised with its breakthrough liquid biopsy test, the Guardant360 ®.

Guardant Health Asia, Middle East & Africa (AMEA) has won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2021. Its breakthrough liquid biopsy test, the Guardant360®, helps guide treatment decisions for patients with advanced stage cancer in 41 countries across AMEA. 

We are absolutely delighted to receive this innovation award from Healthcare Asia. Constantly improving our liquid biopsy technology and proactively looking for new ways to best serve our cancer patients are at the heart of everything we do. Time to treatment is crucial and our tests short turnaround time of seven days upon blood sample receipt in the laboratory is very useful for cancer patients in matching them to appropriate treatment quickly, said Simranjit Singh, Chief Executive Officer of Guardant Health AMEA.  

In August last year, Guardant Health's Guardant360® CDx became the first liquid biopsy to receive approval from the U.S. Food and Drug Administration (FDA) for comprehensive tumor mutation profiling across all solid cancers. Guardant Health AMEA has also recently submitted their liquid biopsy for regulatory approval in Japan. With the increasing number of approved targeted therapies by the FDA, the need for comprehensive genomic profiling is becoming an integral part of treatment selection.

Guardant Health AMEA has been hosting webinars to facilitate peer-to-peer education with leading oncologists sharing their patient cases using the Guardant360 test. Having successfully led 18 webinars in 2020, Guardant Health AMEA shared best practices in the liquid biopsy space with hundreds of medical oncologists in AMEA who attended these webinars. Continuing Medical Education (CME) credits were offered at these webinars by working with medical oncology societies in the region. 

In efforts to help this vulnerable group of cancer patients during this COVID-19 pandemic, Guardant Health AMEA has begun offering mobile phlebotomy services. This is a welcomed initiative from the patients who find it difficult to travel to hospitals to get tested or get invasive tissue biopsies done. 

Guardant Health AMEAs patient-centric approach is what drives the company to constantly innovate and do their part in helping cancer patients in AMEA. This drive is further fuelled by their desire to excel in their field, one that Healthcare Asia honours by endowing them this award.

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox
It was recognised for its cutting-edge medical device packaging design, Dispenser Integrated System Kit (DISK).
There has been an expanding research base across India, China, and Japan.
It combines third-party assured data verification with blockchain technology.
Consultation is available for only $0.014 (INR1).
The number of hospitals operating on hip fracture that have access to a fracture liaison service has been steadily rising from 2013 to 2020.
GMT Manila’s award-winning initiative, in collaboration with Endec Inc. and Scilore LLC, is a rapidly deployable turnkey solution for RT-PCR Testing that made it more available across the Philippines. 
As The National Cardiovascular Referral Center in Indonesia, NCCHK has been acknowledged by Asia's Healthcare Industry.
Currently, North America dominates the market across the globe.
More medical devices are being bought for home use.
It has also introduced a new hotline service.
The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.
It took home the Training Initiative of the Year trophy for its non-invasive therapy treatment for benign prostatic hyperplasia (BPH).
The country’s SII makes up about half of Covax supply.
It owns 39 hospitals and eight clinics across England, Wales, and Scotland.
The company plans to set up over 100 in-school clinics.